Avantax Advisory Services Inc. Sells 814 Shares of Hologic, Inc. (NASDAQ:HOLX)

Avantax Advisory Services Inc. lessened its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 17.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 3,894 shares of the medical equipment provider’s stock after selling 814 shares during the period. Avantax Advisory Services Inc.’s holdings in Hologic were worth $281,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of HOLX. Benson Investment Management Company Inc. acquired a new stake in shares of Hologic in the 4th quarter valued at $4,832,000. Principal Financial Group Inc. boosted its position in Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider’s stock valued at $19,547,000 after buying an additional 1,606 shares in the last quarter. Clean Yield Group grew its stake in Hologic by 18.9% during the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock worth $3,291,000 after buying an additional 7,266 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock worth $2,344,000 after buying an additional 800 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Hologic in the third quarter valued at approximately $2,350,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Stephens reissued an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday, February 6th. Needham & Company LLC lowered shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a report on Monday, February 3rd. Evercore ISI dropped their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research note on Thursday, February 6th. William Blair reissued an “outperform” rating on shares of Hologic in a report on Thursday, February 6th. Finally, Leerink Partnrs lowered Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus price target of $84.62.

Hologic Trading Down 1.8 %

Shares of HOLX stock opened at $60.80 on Wednesday. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67. The company has a market capitalization of $13.64 billion, a PE ratio of 19.18, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The firm has a 50 day moving average price of $65.70 and a two-hundred day moving average price of $73.66. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.